BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33840228)

  • 1. Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.
    Zelniker TA; Morrow DA; Scirica BM; Furtado JD; Guo J; Mozaffarian D; Sabatine MS; O'Donoghue ML
    J Am Heart Assoc; 2021 Apr; 10(8):e017401. PubMed ID: 33840228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
    Scirica BM; Morrow DA; Budaj A; Dalby AJ; Mohanavelu S; Qin J; Aroesty J; Hedgepeth CM; Stone PH; Braunwald E
    J Am Coll Cardiol; 2009 Apr; 53(16):1411-21. PubMed ID: 19371824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
    O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial.
    Morrow DA; Scirica BM; Sabatine MS; de Lemos JA; Murphy SA; Jarolim P; Theroux P; Bode C; Braunwald E
    J Am Coll Cardiol; 2010 Mar; 55(12):1189-1196. PubMed ID: 20298924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial).
    Harkness JR; Morrow DA; Braunwald E; Ren F; Lopez-Sendon J; Bode C; Budaj A; Scirica BM
    Am J Cardiol; 2011 Nov; 108(10):1373-81. PubMed ID: 21890090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
    Nieminen T; Scirica BM; Pegler JR; Tavares C; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Umez-Eronini AA; Morrow DA; Belardinelli L; Verrier RL
    Am J Cardiol; 2014 Jul; 114(1):17-23. PubMed ID: 24852915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter by Madias regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial".
    Madias JE
    Circulation; 2011 Apr; 123(14):e403; author reply e405. PubMed ID: 21482970
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Braunwald E; Belardinelli L; Hedgepeth CM; Spinar J; Wang W; Qin J; Karwatowska-Prokopczuk E; Verheugt FW; Morrow DA
    Circulation; 2010 Aug; 122(5):455-62. PubMed ID: 20644019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma phospholipid long-chain ω-3 fatty acids and total and cause-specific mortality in older adults: a cohort study.
    Mozaffarian D; Lemaitre RN; King IB; Song X; Huang H; Sacks FM; Rimm EB; Wang M; Siscovick DS
    Ann Intern Med; 2013 Apr; 158(7):515-25. PubMed ID: 23546563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter by Ayalloore and LeLorier regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial".
    Ayalloore SG; LeLorier P
    Circulation; 2011 Apr; 123(14):e404; author reply e405. PubMed ID: 21482971
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
    Mega JL; Hochman JS; Scirica BM; Murphy SA; Sloan S; McCabe CH; Merlini P; Morrow DA
    Circulation; 2010 Apr; 121(16):1809-17. PubMed ID: 20385930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
    Karwatowska-Prokopczuk E; Wang W; Cheng ML; Zeng D; Schwartz PJ; Belardinelli L
    Europace; 2013 Mar; 15(3):429-36. PubMed ID: 23258816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of n-3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-based (JPHC) study.
    Hamazaki K; Iso H; Eshak ES; Ikehara S; Ikeda A; Iwasaki M; Hamazaki T; Tsugane S;
    Atherosclerosis; 2018 May; 272():226-232. PubMed ID: 29277442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.
    Bonaca MP; Scirica BM; Sabatine MS; Jarolim P; Murphy SA; Chamberlin JS; Rhodes DW; Southwick PC; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2012 Jul; 60(4):332-8. PubMed ID: 22813612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36.
    Bonaca MP; O'Malley RG; Murphy SA; Jarolim P; Conrad MJ; Braunwald E; Sabatine MS; Morrow DA
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):431-40. PubMed ID: 25538086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes.
    Fanaroff AC; Roe MT; Clare RM; Lokhnygina Y; Navar AM; Giugliano RP; Wiviott SD; Tershakovec AM; Braunwald E; Blazing MA
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28923989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
    Kohli P; Bonaca MP; Kakkar R; Kudinova AY; Scirica BM; Sabatine MS; Murphy SA; Braunwald E; Lee RT; Morrow DA
    Clin Chem; 2012 Jan; 58(1):257-66. PubMed ID: 22096031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.